Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Localized Prostate Cancer
Interventions: TOOKAD Soluble 4 mg/kg; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: talazoparib plus enzalutamide, Placebo plus enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more

Conditions: Prostate Cancer Metastatic, Prostate Cancer
Interventions: Exercise Intervention; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Core Needle TRUS Needle biopsy (Transrectal ultrasound), Core Needle MRI/US image fusion guided needle biopsy; Procedure
Lead sponsor: Philips Healthcare; Industry
Eligibility: 18 Years to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Prostate Carcinoma
Interventions: Undergo HRV and wear accelerometer to assess therapy complications, Dual X-ray Absorptiometry, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 36
States / cities: Hoover, Alabama • Springdale, Arizona • Tucson, Arizona + 33 more

Conditions: Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease
Interventions: Itraconazole; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: lapatinib ditosylate; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina

Conditions: Prostate Cancer
Interventions: flotufolastat (18F), piflufolastat (18F); Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Amifostine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Caris Science, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AB-3028; Biological
Lead sponsor: Arsenal Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 6 more

Conditions: Prostate Cancer
Interventions: iRAI; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: PET/CT, PET/MRI; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Dehydrated alcohol, Lidocaine IV; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: microarray analysis, diagnostic laboratory biomarker analysis; Genetic · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 10
States / cities: Atlanta, Georgia • Springfield, Illinois • City of Saint Peters, Missouri + 4 more

Conditions: Prostate Cancer
Interventions: MUC-2-KLH vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: GT0918; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Towson, Maryland • Omaha, Nebraska • Las Vegas, Nevada + 3 more

Conditions: Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction, Sexuality and Reproductive Issues
Interventions: counseling intervention, questionnaire administration, psychosocial assessment and care; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Vitamin D, soy; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer
Interventions: rhPSMA-7.3 (18F) Injection, Positron emission tomography scan; Drug · Diagnostic Test
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chicago, Illinois • LaGrange, Illinois

Search by objective public record fields.

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Exercise in Prostate Cancer

MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer

Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

EMBRACE1: Prostate Biorepository

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Long Acting Neuraxial Peri-prostatic Block in Cancer

Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer